Related Experiment Video
Updated: Aug 5, 2025

Characterizing RNA Modifications in Single Neurons Using Mass Spectrometry
Published on: April 21, 2022
Role of N6-methyladenosine modification in central nervous system diseases and related therapeutic agents
Junya Lv1, Lijuan Xing2, Xin Zhong1
1School of Pharmacy, Department of Pharmacology, China Medical University, Shenyang 110122, China.
Abstract:
N6-methyladenosine (m6A) is a ubiquitous mRNA modification in eukaryotes. m6A occurs through the action of methyltransferases, demethylases, and methylation-binding proteins. m6A methylation of RNA is associated with various neurological disorders, including Alzheimer's disease (AD), Parkinson's disease (PD), depression, cerebral apoplexy, brain injury, epilepsy, cerebral arteriovenous malformations, and glioma. Furthermore, recent studies report that m6A-related drugs have attracted considerable concerns in the therapeutic areas of neurological disorders. Here, we mainly summarized the role of m6A modification in neurological diseases and the therapeutic potential of m6A-related drugs. The aim of this review is expected to be useful to systematically assess m6A as a new potential biomarker and develop innovative modulators of m6A for the amelioration and treatment of neurological disorders.
Related Concept Videos
RNA Editing
Biosynthesis of Nucleic Acids
Drugs Affecting Neurotransmitter Synthesis
Nuclear Export of mRNA
Phase II Reactions: Methylation Reactions
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
Alzheimer's Disease: Treatment

